Should I buy or sell Immunome stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNM shares. View IMNM analyst ratings or view top-rated stocks .

What is Immunome's stock price target for 2024?

6 brokerages have issued twelve-month price objectives for Immunome's shares. Their IMNM share price targets range from $30.00 to $35.00. On average, they expect the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 107.5% from the stock's current price. View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts .

How have IMNM shares performed in 2024?

Immunome's stock was trading at $10.70 at the start of the year. Since then, IMNM stock has increased by 47.1% and is now trading at $15.74. View the best growth stocks for 2024 here .

When is Immunome's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our IMNM earnings forecast .

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative net margin of 761.92% and a negative trailing twelve-month return on equity of 69.74%.

What ETF holds Immunome's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 66,447 shares of IMNM stock, representing 0.93% of its portfolio.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)

Free IMNM Stock Alerts

$15.48

-1.70 (-9.90%)

(As of 04:37 PM ET)

Compare

Today's Range: $15.42
▼
$17.31
50-Day Range: $17.18
▼
$27.34
52-Week Range: $4.44
▼
$30.96

Volume: 2.10 million shs
Average Volume: 717,466 shs
Market Capitalization: $924.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.67

Get Immunome alerts:

Immunome MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 107.5% Upside
$32.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.91) to ($2.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

644th out of 918 stocks

Pharmaceutical Preparations Industry

285th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immunome has only been the subject of 4 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for IMNM.

0.0

Dividend Strength

Dividend Yield
Immunome does not currently pay a dividend.
Dividend Growth
Immunome does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMNM.

3.2

News and Social Media Coverage

News Sentiment
Immunome has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Immunome this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunome insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.00% of the stock of Immunome is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunome are expected to decrease in the coming year, from ($1.91) to ($2.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunome is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunome is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunome has a P/B Ratio of 5.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Immunome Stock (NASDAQ:IMNM)

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IMNM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMNM Stock News Headlines

April 19, 2024 | finance.yahoo.com

Immunome, Inc. (IMNM)

April 18, 2024 | americanbankingnews.com

Immunome, Inc. (NASDAQ:IMNM) Receives $31.50 Consensus Target Price from Brokerages

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 17, 2024 | msn.com

Immunome (IMNM) Price Target Increased by 8.72% to 36.04

April 17, 2024 | americanbankingnews.com

Immunome (NASDAQ:IMNM) Shares Gap Up to $20.58

April 16, 2024 | msn.com

Guggenheim Initiates Coverage of Immunome (IMNM) with Buy Recommendation

April 16, 2024 | americanbankingnews.com

Immunome (NASDAQ:IMNM) Receives New Coverage from Analysts at Guggenheim

April 5, 2024 | businesswire.com

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 29, 2024 | investorplace.com

IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023

March 28, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)

March 28, 2024 | businesswire.com

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

March 28, 2024 | businesswire.com

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

March 27, 2024 | finance.yahoo.com

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

March 22, 2024 | finance.yahoo.com

Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions

March 18, 2024 | msn.com

Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies

March 18, 2024 | businesswire.com

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

March 7, 2024 | businesswire.com

Immunome to Participate in the Leerink Partners Global Biopharma Conference

March 1, 2024 | businesswire.com

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

February 28, 2024 | msn.com

Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?

February 24, 2024 | msn.com

Immunome (IMNM) Price Target Increased by 179.17% to 34.17

February 22, 2024 | benzinga.com

Immunome Stock (NASDAQ:IMNM), Short Interest Report

February 20, 2024 | finance.yahoo.com

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 20, 2024 | businesswire.com

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 19, 2024 | finance.yahoo.com

IMNM Apr 2024 30.000 call

February 19, 2024 | finance.yahoo.com

IMNM Mar 2024 10.000 put

February 17, 2024 | ca.finance.yahoo.com

IMNM Jul 2024 25.000 put

See More Headlines

Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMNM
CUSIP: N/A
CIK: 1472012
Web: immunome.com
Phone: 610-321-3700
Fax: N/A
Employees: 37
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.67
High Stock Price Target: $35.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +107.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,810,000.00
Net Margins: -761.92%
Pretax Margin: -761.92%
Return on Equity: -69.74%
Return on Assets: -31.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.63
Quick Ratio: 6.63

Sales & Book Value

Annual Sales: $14.02 million
Price / Sales: 67.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.77 per share
Price / Book: 5.68

Miscellaneous

Outstanding Shares: 59,690,000
Free Float: 47,755,000
Market Cap: $939.52 million
Optionable: Optionable
Beta: 1.66

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Clay B. Siegall Ph.D. (Age 63)
President, CEO & Chairman
Mr. Max Rosett (Age 34)
Interim CFO & Executive VP of Operations
Mr. Robert Lapetina (Age 49)
Principal Accounting Officer
Mr. Philip Roberts
Chief Technical Officer
Dr. Jack Higgins Ph.D. (Age 44)
Chief Scientific Officer
Ms. Sandra G. Stoneman Esq. (Age 51)
J.D., Chief Legal Officer, General Counsel & Corporate Secretary
Comp: $443.43k
Mr. Bruce Turner M.D. (Age 61)
Ph.D., Chief Strategy Officer
Dr. Robert J. Lechleider M.D.
Chief Medical Officer
Mr. Kinney Horn (Age 49)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunome stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNM shares.
View IMNM analyst ratings or view top-rated stocks.
What is Immunome's stock price target for 2024?: 6 brokerages have issued twelve-month price objectives for Immunome's shares. Their IMNM share price targets range from $30.00 to $35.00. On average, they expect the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 107.5% from the stock's current price.
View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts.
How have IMNM shares performed in 2024?: Immunome's stock was trading at $10.70 at the start of the year. Since then, IMNM stock has increased by 47.1% and is now trading at $15.74.
View the best growth stocks for 2024 here.
When is Immunome's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our IMNM earnings forecast.

How were Immunome's earnings last quarter?: Immunome, Inc. (NASDAQ:IMNM) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative net margin of 761.92% and a negative trailing twelve-month return on equity of 69.74%.
What ETF holds Immunome's stock?: Invesco Dorsey Wright Healthcare Momentum ETF holds 66,447 shares of IMNM stock, representing 0.93% of its portfolio.
When did Immunome IPO?: Immunome (IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.
How do I buy shares of Immunome?: Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunome (IMNM) Stock Price, News & Analysis

Immunome MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immunome Stock (NASDAQ:IMNM)

IMNM Stock Price History

IMNM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMNM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™